Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Download (PDF, 136.6KB) -
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at CROI.
Download (PDF, 160.0KB) -
GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
We are committing up to $2 million in 2024 to support adult immunization and health equity programs.
Download (PDF, 158.4KB) -
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.
Download (PDF, 250.5KB) -
GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
-
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare announces U.S. FDA approval of Dovato for the treatment of HIV-1 infection in adolescents 12 years of age and older.
Download (PDF, 236.4KB) -
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Download (PDF, 186.4KB) -
New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Download (PDF, 192.8KB) -
US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Download (PDF, 189.3KB) -
FDA approves Benlysta (belimumab) Autoinjector for children with systemic lupus erythematosus
FDA approves GSK's 200mg subcutaneous Benlysta for patients five years of age or older. A treatment to inhibit B-lymphocyte stimulator.
Download (PDF, 100.1KB) -
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases
Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
-
New data at ASCO showcases the transformational potential of GSK's oncology portfolio
Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.
Download (PDF, 374.8KB) -
Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling
GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.
-
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
Download (PDF, 272.9KB) -
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Download (PDF, 126.4KB) -
US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
GSK announced FDA approval of AREXVY Vaccine to prevent LRTD in adults aged 50-59 at heightened risk.
Download (PDF, 207.2KB) -
Statement: Zantac (ranitidine) litigation – Kasza case
GSK welcomes the plaintiff’s voluntary dismissal of the next Zantac case (Kasza).
-
Statement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision
GSK confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court.
Download (PDF, 132.5KB) -
Students nationwide take on the role of space scientists during GSK science in the summer™ in collaboration with the Franklin Institute
Students across the US participate in the free GSK Science in the Summer™ program, partnered with The Franklin Institute.
Download (PDF, 336.0KB)
